Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arndt Hartmann

Showing results (911-920 of 933) with videos related to

Pageof 94
Sort By:
British Journal of Cancer|June 20, 2020
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis ConsortiumFilipe Correia Martins, Dominique-Laurent Couturier, Anna Paterson, et al.
Lancet (London, England)|May 15, 2018
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy studyFranck Pagès, Bernhard Mlecnik, Florence Marliot, et al.
JAMA Oncology|October 20, 2017
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer, Ellen L Goode, Matthew S Block, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Carcinogenesis|December 12, 2013
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancerKristen S Purrington, Susan Slager, Diana Eccles, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2022
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse OutcomesNicola S Meagher, Kylie L Gorringe, Matthew Wakefield, et al.
The Journal of Pathology. Clinical Research|March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium studyMartin Köbel, Eun-Young Kang, Ashley Weir, et al.
European Urology|November 23, 2019
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>†</sup>: Under the Auspices of the EAU-ESMO Guidelines CommitteesJ Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Virchows Archiv : an International Journal of Pathology|November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Joshua Millstein, Gordana Popovic, et al.
Pageof 94

Showing results (911-920 of 933) with videos related to

Sort By:
Pageof 94
British Journal of Cancer|June 20, 2020
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis ConsortiumFilipe Correia Martins, Dominique-Laurent Couturier, Anna Paterson, et al.
Lancet (London, England)|May 15, 2018
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy studyFranck Pagès, Bernhard Mlecnik, Florence Marliot, et al.
JAMA Oncology|October 20, 2017
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer, Ellen L Goode, Matthew S Block, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Carcinogenesis|December 12, 2013
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancerKristen S Purrington, Susan Slager, Diana Eccles, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2022
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse OutcomesNicola S Meagher, Kylie L Gorringe, Matthew Wakefield, et al.
The Journal of Pathology. Clinical Research|March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium studyMartin Köbel, Eun-Young Kang, Ashley Weir, et al.
European Urology|November 23, 2019
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>†</sup>: Under the Auspices of the EAU-ESMO Guidelines CommitteesJ Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Virchows Archiv : an International Journal of Pathology|November 16, 2021
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinomaEun Young Kang, Joshua Millstein, Gordana Popovic, et al.
Pageof 94